DRALSERP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DRALSERP (DRALSERP).
Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.
| Metabolism | Primarily hepatic via CYP2D6, CYP1A2, and CYP3A4; active metabolite: reserpiline. |
| Excretion | Primarily hepatic metabolism to inactive metabolites; less than 1% excreted unchanged in urine; approximately 10% eliminated in feces. |
| Half-life | Terminal elimination half-life is 45 to 50 hours; clinically significant as drug accumulates with repeated dosing, requiring careful titration. |
| Protein binding | Approximately 96% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 200 L/kg; extensive tissue distribution, particularly to adipose tissue. |
| Bioavailability | Oral bioavailability is 50% to 60% due to extensive first-pass metabolism. |
| Onset of Action | Oral: 2 to 4 hours for initial hypotensive effect; maximal effect at 3 to 6 weeks of continuous therapy. |
| Duration of Action | Oral: Hypotensive effect lasts 24 to 48 hours after a single dose; with chronic dosing, effect persists for weeks after discontinuation due to long half-life. |
0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.
| Dosage form | TABLET |
| Renal impairment | No specific adjustment required; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), reduce dose by 50%. |
| Pediatric use | Not recommended for use in pediatric patients. |
| Geriatric use | Start at 0.125 mg orally once daily; titrate slowly to avoid excessive sedation and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DRALSERP (DRALSERP).
| Breastfeeding | Excreted into breast milk; M/P ratio approximately 0.5. Potential for adverse effects in the infant, including bradycardia and sedation. Not recommended during breastfeeding. |
| Teratogenic Risk | First trimester: Associated with increased risk of congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal hypotension. Avoid throughout pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Risk of depression and suicidal ideation; contraindicated in patients with a history of depression, suicidal tendencies, or Parkinson's disease.
| Serious Effects |
History of depression or suicidal tendencies; active peptic ulcer disease; ulcerative colitis; patients receiving electroconvulsive therapy; concurrent MAO inhibitors; hypersensitivity.
| Precautions | May cause severe depression, suicidal thoughts, and extrapyramidal symptoms; avoid in patients with history of peptic ulcer disease (increases gastric acid secretion); may cause nasal congestion, bradycardia, and hypotension; use caution during surgery due to increased vagal tone. |
Loading safety data…
| Monitor maternal blood pressure and heart rate; fetal ultrasound for growth and amniotic fluid volume; neonatal monitoring for hypotension and bradycardia after delivery. |
| Fertility Effects | May impair female fertility by disrupting ovulatory function; reversible upon discontinuation. In males, may cause erectile dysfunction and reduced libido. |